Marker Therapeutics Inc MRKR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
-
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
Trading Information
- Previous Close Price
- $2.58
- Day Range
- $2.65–2.92
- 52-Week Range
- $2.40–6.16
- Bid/Ask
- $2.75 / $2.83
- Market Cap
- $24.54 Mil
- Volume/Avg
- 41,514 / 27,285
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- http//www.markertherapeutics.com
Valuation
|
Metric
|
MRKR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
MRKR
Financial Strength
|
Metric
|
MRKR
|
|---|---|
Quick Ratio | 5.22 |
Current Ratio | 5.92 |
Interest Coverage | — |
Quick Ratio
MRKR
Profitability
|
Metric
|
MRKR
|
|---|---|
Return on Assets (Normalized) | −58.95% |
Return on Equity (Normalized) | −69.75% |
Return on Invested Capital (Normalized) | −73.58% |
Return on Assets
MRKR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lrdtptfnf | Hsfzw | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nkhplmzgm | Zlggx | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jmsnzlw | Ctjkr | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tgzbxcdc | Bnsmfh | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Sfwxslxv | Tvyv | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Czngndjr | Mmbz | $28.0 Bil | |||
| Moderna Inc
MRNA
| Xpdmkgl | Hzqrl | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Ffbgkfn | Phnh | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ysjvygwd | Kzbgqp | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Rnpmhyjkr | Vpgtdn | $12.6 Bil |
United States